Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

P. M. Ridker*, J. Revkin, P. Amarenco, R. Brunell, M. Curto, F. Civeira, M. Flather, R. J. Glynn, J. Gregoire, J. W. Jukema, Y. Karpov, J. J. P. Kastelein, W. Koenig, A. Lorenzatti, P. Manga, U. Masiukiewicz, M. Miller, A. Mosterd, J. Murin, J. C. NicolauS. Nissen, P. Ponikowski, R. D. Santos, P. F. Schwartz, H. Soran, H. White, R. S. Wright, M. Vrablik, C. Yunis, C. L. Shear, SPIRE Cardiovascular Outcome Inve, Abraham Kroon, J. -C. Tardif

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1527-1539
Number of pages13
JournalNew England Journal of Medicine
Volume376
Issue number16
DOIs
Publication statusPublished - 20 Apr 2017

Keywords

  • STATIN THERAPY
  • GENETIC-VARIANTS
  • REDUCING LIPIDS
  • EVENTS
  • METAANALYSIS
  • PCSK9
  • REDUCTION
  • TRIALS

Cite this

Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., Karpov, Y., Kastelein, J. J. P., Koenig, W., Lorenzatti, A., Manga, P., Masiukiewicz, U., Miller, M., Mosterd, A., Murin, J., ... Tardif, J. -C. (2017). Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 376(16), 1527-1539. https://doi.org/10.1056/NEJMoa1701488